Federated Hermes Inc. Purchases 106,885 Shares of Takeda Pharmaceutical Co. (NYSE:TAK)

Key Points

• Federated Hermes Inc. increased its stake in Takeda Pharmaceutical Co. by 24.6% during the 1st quarter, owning a total of 541,919 shares valued at approximately $8.06 million.
• Other institutional investors have also boosted their holdings significantly, including Soleus Capital Management, which raised its stake by 136.0% in the previous quarter.
• Takeda Pharmaceutical reported an EPS of $0.16 for the last quarter, missing expectations and generating revenue of $7.34 billion, below analysts' estimates of $8.02 billion.

Federated Hermes Inc. lifted its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 24.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 541,919 shares of the company's stock after purchasing an additional 106,885 shares during the period. Federated Hermes Inc.'s holdings in Takeda Pharmaceutical were worth $8,058,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of TAK. FNY Investment Advisers LLC purchased a new stake in shares of Takeda Pharmaceutical in the 1st quarter valued at about $37,000. Farther Finance Advisors LLC lifted its stake in Takeda Pharmaceutical by 29.2% in the first quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock worth $69,000 after purchasing an additional 1,045 shares during the last quarter. Fifth Third Bancorp increased its position in shares of Takeda Pharmaceutical by 85.5% in the first quarter. Fifth Third Bancorp now owns 5,232 shares of the company's stock valued at $78,000 after acquiring an additional 2,411 shares during the period. Point72 Hong Kong Ltd purchased a new position in shares of Takeda Pharmaceutical in the fourth quarter valued at about $94,000. Finally, GAMMA Investing LLC increased its position in shares of Takeda Pharmaceutical by 22.6% during the first quarter. GAMMA Investing LLC now owns 7,042 shares of the company's stock valued at $105,000 after buying an additional 1,296 shares during the period. Hedge funds and other institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Up 0.7%

TAK traded up $0.11 during midday trading on Monday, reaching $14.27. The company's stock had a trading volume of 7,655,754 shares, compared to its average volume of 5,028,765. The firm has a market capitalization of $45.39 billion, a price-to-earnings ratio of 9.19 and a beta of 0.22. The company has a current ratio of 1.16, a quick ratio of 0.59 and a debt-to-equity ratio of 0.60. Takeda Pharmaceutical Co. has a 1 year low of $12.80 and a 1 year high of $15.53. The stock's 50-day moving average is $14.86 and its 200-day moving average is $14.53.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. The firm had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. As a group, research analysts expect that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.